A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
- Conditions
- Severe Asthma
- Interventions
- Drug: Verekitug (UPB-101)Drug: Placebo
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Upstream Bio Inc.
- Target Recruit Count
- 436
- Registration Number
- NCT06196879
- Locations
- 🇨🇦
Dynamic Drug Advancement, Ajax, Ontario, Canada
🇨🇦Ottawa Allergy Research Corp, Ottawa, Ontario, Canada
🇮🇹UOSD Allergologia e Immunodeficienze dell'A.O.U. Federico II, Napoli, Italy
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
- Conditions
- InfluenzaCOVID-19
- Interventions
- Biological: Licensed influenza vaccineBiological: Influenza and COVID-19 Combination ABiological: Influenza and COVID-19 Combination BBiological: Investigational influenza vaccineBiological: Placebo
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 8798
- Registration Number
- NCT06178991
- Locations
- 🇺🇸
Velocity Clinical Research, Cincinnati, Mt. Auburn, Cincinnati, Ohio, United States
🇺🇸North Alabama Research Center, Athens, Alabama, United States
🇺🇸Accel Research Sites - Birmingham Clinical Research Unit, Birmingham, Alabama, United States
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
- Conditions
- GrippeInfluenzaVaccines
- Interventions
- Biological: pdmFlu vaccineBiological: PlaceboBiological: Licensed influenza vaccine
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 157
- Registration Number
- NCT06179446
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
🇺🇸Research Centers of America ( Hollywood ), Hollywood, Florida, United States
🇺🇸NYU Langone Health, New York, New York, United States
Follow-up Study of Autologous Transplantation of P63+ Lung Progenitor Cells for Treatment of Bronchiectasis
- Conditions
- Bronchiectasis
- Interventions
- Other: RNA sequencing is performed on the remaining LPCsOther: Immunofluorescence staining is performed in the surgically resected lung tissue sections
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06164093
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
- Conditions
- RhinovirusVirus Infection, RNAEnterovirus InfectionsRespiratory Tract DiseasesUpper Respiratory DiseaseUpper Respiratory DisorderInfections, RespiratoryCopdCOPD Exacerbation AcuteRhinovirus Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Altesa Biosciences, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT06149494
- Locations
- 🇬🇧
St. Mary's Hospital - Imperial College Respiratory Research Unit (ICRRU), London, United Kingdom
Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults
- Conditions
- Influenza, Human
- Interventions
- Biological: ARCT-2138Biological: Licensed Quadrivalent Vaccine for younger adultsBiological: Licensed Quadrivalent Vaccine for older adults
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Arcturus Therapeutics, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT06125691
- Locations
- 🇦🇺
Emeritus Research Camberwell, Melbourne, Victoria, Australia
🇦🇺Nucleus Network Brisbane Clinic, Brisbane, Queensland, Australia
Incidence of Viral Hepatitis D Relapses Upon Discontinuation of Bulevirtide in Patients With Chronic Hepatitis D and Negative HDV RNA
- Conditions
- Chronic Hepatitis D
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Center of target therapy
- Target Recruit Count
- 24
- Registration Number
- NCT06121427
- Locations
- 🇷🇺
Center of Target Therapy, Moscow, Russian Federation
Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Other: RNA sequencing
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Target Recruit Count
- 192
- Registration Number
- NCT06083584
- Locations
- 🇫🇷
CHU de Montpellier, Montpellier, France
🇫🇷CHU de Nîmes, Nîmes, France
🇫🇷CHU de Lyon, Lyon, France
Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients
- Conditions
- Alzheimer Disease
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- MaxWell Clinic, PLC
- Target Recruit Count
- 43
- Registration Number
- NCT06079827
- Locations
- 🇺🇸
The MaxWell Clinic, Brentwood, Tennessee, United States
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 163
- Registration Number
- NCT06069544
- Locations
- 🇺🇸
AMR Tempe, Tempe, Arizona, United States
🇺🇸University of Maryland, Center for Vaccine Development, Baltimore, Maryland, United States
🇺🇸AMR Las Vegas, Las Vegas, Nevada, United States